SLAM
ADMA icon

Swiss Life Asset Management’s ADMA Biologics ADMA Stock Holding History

Swiss Life Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$265K Buy
31,623
+16,399
+108% +$149K ﹤0.01% 1352
2026
Q1 		$137K Buy
15,224
+3,922
+35% +$61.9K ﹤0.01% 1440
2025
Q4 		$206K Hold
11,302
– – ﹤0.01% 1268
2025
Q3 		$166K Buy
+11,302
New +$194K ﹤0.01% 1132

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Swiss Life Asset Management's ADMA Position: Q2 2026 in Review

Swiss Life Asset Management increased its ADMA Biologics (ADMA) stake by 108% in Q2 2026, buying an estimated $149K and bringing the position to 31,623 shares worth $265K. The position accounts for ﹤0.01% of the portfolio, ranked #1352.

Swiss Life Asset Management first reported a position in ADMA in Q3 2025 and has held it in 4 quarters since. 191 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Swiss Life Asset Management held 31,623 shares of ADMA Biologics worth $265K as of Q2 2026.
  • Swiss Life Asset Management bought 16,399 ADMA Biologics shares in Q2 2026, an estimated $149K.
  • ADMA Biologics made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #1352 holding.
  • Swiss Life Asset Management first reported a position in ADMA Biologics in Q3 2025 and has held it in 4 quarters since.
  • 191 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.